A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.

Stopped This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.

Conditions

• Pain

Interventions

• DRUG: [S,S]-Reboxetine

Sponsor

Pfizer